5OX1
Glycogen Phosphorylase in complex with JLH270
Summary for 5OX1
Entry DOI | 10.2210/pdb5ox1/pdb |
Related | 5OWY 5OWZ 5OX0 |
Descriptor | Glycogen phosphorylase, muscle form, (2~{R},3~{S},4~{R},5~{R},6~{S})-2-(hydroxymethyl)-6-[5-(4-methoxyphenyl)-1~{H}-1,2,4-triazol-3-yl]oxane-3,4,5-triol, DIMETHYL SULFOXIDE, ... (5 entities in total) |
Functional Keywords | transferase |
Biological source | Oryctolagus cuniculus (Rabbit) |
Total number of polymer chains | 1 |
Total formula weight | 98085.00 |
Authors | Kyriakis, E.,Stravodimos, G.A.,Kantsadi, A.L.,Chatzileontiadou, D.S.M.,Leonidas, D.D. (deposition date: 2017-09-05, release date: 2018-02-28) |
Primary citation | Kyriakis, E.,Solovou, T.G.A.,Kun, S.,Czifrak, K.,Szocs, B.,Juhasz, L.,Bokor, E.,Stravodimos, G.A.,Kantsadi, A.L.,Chatzileontiadou, D.S.M.,Skamnaki, V.T.,Somsak, L.,Leonidas, D.D. Probing the beta-pocket of the active site of human liver glycogen phosphorylase with 3-(C-beta-d-glucopyranosyl)-5-(4-substituted-phenyl)-1, 2, 4-triazole inhibitors. Bioorg. Chem., 77:485-493, 2018 Cited by PubMed Abstract: Human liver glycogen phosphorylase (hlGP), a key enzyme in glycogen metabolism, is a valid pharmaceutical target for the development of new anti-hyperglycaemic agents for type 2 diabetes. Inhibitor discovery studies have focused on the active site and in particular on glucopyranose based compounds with a β-1 substituent long enough to exploit interactions with a cavity adjacent to the active site, termed the β-pocket. Recently, C-β-d-glucopyranosyl imidazoles and 1, 2, 4-triazoles proved to be the best known glucose derived inhibitors of hlGP. Here we probe the β-pocket by studying the inhibitory effect of six different groups at the para position of 3-(β-d-glucopyranosyl phenyl)-5-phenyl-, 1, 2, 4-triazoles in hlGP by kinetics and X-ray crystallography. The most bioactive compound was the one with an amine substituent to show a K value of 0.43 μM. Structural studies have revealed the physicochemical diversity of the β-pocket providing information for future rational inhibitor design studies. PubMed: 29454281DOI: 10.1016/j.bioorg.2018.02.008 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.85 Å) |
Structure validation
Download full validation report